CANCUN HOC 2016 - incan-mexico.org HOC 2016.pdfRamiro Espinoza, MD 13:00-13:40 Magistral Conference...
Transcript of CANCUN HOC 2016 - incan-mexico.org HOC 2016.pdfRamiro Espinoza, MD 13:00-13:40 Magistral Conference...
Faculty
Faculty INCan
Dr. Abelardo Meneses GarcíaDirector General
Dr. Eduardo E. Cervera CeballosDirector de Docencia
Dra. Silvia Rivas VeraJefa del Departamento de Hematología
Dr. Jorge O. García MéndezJefe del Departamento de Educación
Médica Continua
Dra. Myrna Candelaria HernándezCoordinadora de la Unidad Funcional
de Hematología
Dr. Sergio Sánchez GuerreroJefe del Departamento de Banco de
Sangre
Dr. Juan R. Labardini MéndezDepartamento de Hematología
Dr. Luis Manuel Valero SaldañaCoordinador del Programa de
Trasplante de Progenitores Hematopoyéticos
Dra. Nidia P. Zapata CantoDepartamento de Hematología
Dra. Ana Florencia Ramírez IbargüenDepartamento de Hematología
Dra. Patricia Baz GutiérrezDepartamento de Hematología
Dr. Ramiro Espinoza ZamoraDepartamento de Hematología
Dra. Karla Espinosa BautistaDepartamento de Hematología
Dr. Carlos Cadena EumañaDepartamento de Hematología
Dr. Flavio Grimaldo GómezDepartamento de Hematología
Faculty National
Dra. Magdalena Bahena GarcíaHospital de Central Sur de Alta
Especialidad de Petróleos MexicanosCiudad de México
Dra. Florencia DelgadoDirector de Asuntos Científicos
“Latinoamérica”
Dra. María Roberta Demichelis Gómez
Instituto Nacional de Ciencias Médicas y Nutrición
“Salvador Zubirán”, Ciudad de México
Dr. Freddy Domínguez Sosa Hospital de Central Sur de Alta
Especialidad de Petróleos MexicanosCiudad de México
Dr. Arturo Galindo Fraga Instituto Nacional de Ciencias Médicas
y Nutrición“Salvador Zubirán”, Ciudad de México
Dr. Renán Góngora BiachiGHEMAS, Mérid, Yuc.
Dr. Pedro González TorresGHEMAS. Mérida, Yuc.
Dr. Luis M. Loarca PiñaHospital Ángeles de Querétaro, Qro.
Dra. Norma López-SantiagoInstituto Nacional de Pediatría, Ciudad
de México
Dr. Gerardo LópezInstituto Nacional de Pediatría, Ciudad
de México
Faculty
Dr. Francisco J. Mijangos HuescaHospital de Central Norte de Alta
Especialidad de Petróleos MexicanosCiudad de México
Dr. Roberto Ovilla MartínezHospital Ángeles de Interlomas,
Ciudad de México
Dr. Oscar de J. Pérez Ramírez CReHCe, San Luis Potosí
Dr. Ramón Rivas LlamasPresidente de la Agrupación Mexicana
para el Estudios de la HematologíaHospital General, Culiacán, Sin.
Dra. Margarita Rodríguez MejoradaGHEMAS, Mérida Yuc.
Dr. Jorge Vela OjedaHospital de Especialidades CMN La
Raza, IMSS
Dr. Luis Mario Villela MartínezHospital General “Fernando
Ocaranza”, ISSSTE, Hermosillo, Son.
Dra. Yenet VenturaInstituto Nacional de Ciencias Médicas
y Nutrición“Salvador Zubirán”, Ciudad de México
Faculty International
Jorge Cortés, MDMD Anderson Cancer Center,
Houston Tx
Luis Fayad, MDMD Anderson Cancer Center,
Houston TxRafael Fonseca MD
Mayo Clinic, Scottsdale AZ, Phoenix
Guillermo García-Manero, MDChief Section of MDS
Deputy Chair Translational ResearchMD Anderson Cancer Center,
Houston Tx
Irene M. Ghobrial, MDAssociate Professor, Medicine, Harvard
Medical SchoolActive Medical Staff, Myeloma Program, Dana-Farber Institute
Hagop Kantarjian, MDProfessor and Chairman Department of
LeukemiaSamsung Distinguished University
Chair in Cancer MedicineMD Anderson Cancer Center,
University of Texas
Partow Kebriaei MDMD Anderson Cancer Center,
Houston Tx
Cesar Nuñez, MDMD Anderson Cancer Center,
Houston Tx
Farhad Ravandi-Kashani, MDChief, Section of Developmental
Therapeutics,Department of Leukemia,
University of Texas – M. D. Anderson Cancer Center
Hilario Mata, MD, PhDMD Anderson Cancer Center,
Houston Tx
Rubén Niesvizky MDDirector Multiple Myeloma Center
Professor of MedicineWeill Cornell Medical College
New York Presbyterian Hospital
Professor
Mapping
Program
August 31/ Wednesday
Mexican PNH Working Group MeetingRoom: Coral Garden
17:00 – 20:00 (By an unrestricted scientific grant by Alexion)
September 1st/Thursday
Mexican PNH Working Group MeetingRoom: Coral Garden
08:00 – 10:00(By an unrestricted scientific grant by Alexion)
By invitation only
Iberoamerican Multiple Myeloma Consortium Annual MeetingRoom: Coral Garden
Coordinators: Eduardo Cervera, MD / Nidia Zapata, MD10:30 – 13:30
OPENING CEREMONYAbelardo Meneses, MD/ Hilario Mata, MD18:00 – 20:00
18:00- 18:15 Welcome Address Instituto Nacional de Cancerología Abelardo Meneses, MD PhD
18:15 – 18: 55 The paradigm of drug pricing in oncology Hagop Kantarjian, MD
18:55- 19:05 Welcome Address Md Anderson Cancer Center Hilario Mata, MD PhD
19:05 – 19:55 Music in Medicine Claudius Conrad, MD PhD
Welcome & Exposition Inaugural Cocktail20:00 – 21:00
September 2nd/Friday
BREAKFAST SYMPOSIUMRoom: Coral Garden
(Satellite symposium by an unrestricted educational grant from Roche Pharmaceuticals)
07:30 - 08:20
RELAPSE/REFRACTORY FOLLICULAR LYMPHOMA: Optimizing Patients Outcomes With Novel anti CD20 antibodies.Coordinator: Oscar Pérez Ramírez, MD.
07:30- 07:45 Breakfast
07:45- 08:20 Magistral conference Luis Fayad, MD
LYMPHOMARoom: Coral Garden
Coordinators: Magdalena Bahena, MD/ Silvia Rivas, MD08:30 – 09:50
08:30 – 08:40 Interactive Clinical case discussion Ana Florencia Ramírez, MD
08:40 – 09:00 Treatment of aggressive NHL, including double hit lymphoma Luis Fayad, MD
09:00 – 09:20 Mantle cell lymphoma. Impact of small molecules on survival Luis Villela, MD
09:20 – 09:40 R-CHOP: does one size fit all in diffuse large B cell Lymphoma? Adrián Ceballos, MD
09:40 – 09:50 Questions & Answers (Round Table) All of the Participants
September 2nd/Friday
INFECTIOUS DISEASESRoom: Coral Garden
Coordinators: Jorge García, MD/ Luis Loarca, MD09:50 – 11:10
09:50 – 10:10 Reactivation of latent infectious diseases with immunochemotherapy: TB, HBV, etc. Freddy Domínguez, MD
10:10 – 10:30 Treatment and contraindication of chemotherapy in systemic fungal infections. Jorge García, MD
10:30 – 10:50 Impact on treatment of hematological malignancies of emergent epidemic diseases. Arturo Galindo, MD
10:50 – 11:10 Questions & Answers (Round Table) All of the Participants
11:10 – 11:20 Coffee Break
PEDIATRIC & YOUNG ADULTSRoom: Coral Garden
Coordinators: Karla Espinosa, MD/ Norma López, MD11:20 – 12:50
11:20 – 11:40 Interactive Clinical case discussion Gerardo López, MD
11:40 – 12:00 Incorporation of small molecules in the treatment of pediatric ALL. Cesar Nuñez, MD
12:00 – 12:20 Monoclonal antibodies in ALL. Roberta de Michelis, MD
12:20 – 12:40 Teenager & young adult lymphoma choosing treatment: like a big boy or an small adult? Ramiro Espinoza, MD.
12:40 – 12:50 Questions & Answers (Round Table) All of the Participants
September 2nd/Friday
MYELOMARoom: Coral Garden
Satellite lunch symposium(By an unrestricted educational grant from CELGENE)
12:50-13:00 Interactive Clinical Case Discussion Ramiro Espinoza, MD
13:00-13:40 Magistral Conference Irene M. Ghobrial, MD
13:40-14:00 Interactive Clinical Case Discussion Ramiro Espinoza, MD
MYELOMARoom: Coral Garden
Coordinators: Margarita Rodríguez, MD/ Jorge Vela, MD14:00 – 15:50
14:00 – 14:20 A critical reappraisal of new standard diagnostic criteria Florencia Delgado, MD
14:20 – 14:40 Interactive Clinical case discussion Margarita Rodríguez, MD
14:40 – 15:00 Investigative tools for diagnosis and management of MM Irene M. Ghobrial, MD
15:00 – 15:20 Insights into the Pathophysiology and Therapeutic Targeting of Treatment Resistance in Myeloma Rafael Fonseca, MD 15:20 – 15:40 A new Direction in treating Multiple Myeloma in the Era of novel Agents “A clinical Perspective” Rubén Niesvizky, MD
15:40 – 15:50 Questions & Answers (Round Table) All of the Participants
September 2nd/Friday
Room: Coral GardenAnnual Nominative Conference“Juan Labardini Méndez MD”
16:00 – 17:00 (A brunch cocktail will be served at the end)16:00 – 16:15 Who is Juan Labardini Méndez, “El Maestro”
Ramiro Espinoza, MD / Eduardo Cervera, MD
Presenter: Pedro González Martínez, MD (10')
16:25 – 17:00 HPN: New concepts of an old hematological disease Renán Góngora, MD
September 3rd/Saturday
TRANSPLANTATIONRoom: Coral Garden
Coordinators: Luis Manuel Valero, MD/ Roberto Ovilla, MD07:30 – 08:50
07:30 – 07:50 Minimal residual disease pre-& postrasplantation. Partow Kebriaei, MD
07:50 – 08:10 Haploidentical transplant in hematological malignancies Luis M. Valero, MD
08:10 – 08:30 Transplantation in Chilhood ALL: Experience at INP Gerardo López, MD
08:30 - 08:40 Interactive Clinical Case Discussion Karla Espinosa, MD
08:40 – 08:50 Questions & Answers (Round Table) All of the Participants
PLENARY SESSIONRoom: Coral Garden
08:50 – 10:30 Integrating new therapeutics tools: from chemo to immunological options Hagop Kantarjian, MD
ACUTE LEUKEMIARoom: Coral Garden
Coordinators: Luis M. Loarca, MD/ Ramón Rivas, MD10:30 – 11:30
10:30 – 10:40 Interactive Clinical case discussion Nidia Zapata, MD
10:40 – 11:00 Refractory AML. Treatment with FLT3 inhibitors Jorge Cortes, MD
11:00 – 11:20 Refractory AML. Treatment with no FLT3 inhibitors Farhad Ravandi, MD
September 3rd/Saturday
11:20 – 11:30 Questions & Answers (Round Table) All of the Participants
11:30 – 11:40 Coffee Break
MDSRoom: Coral Garden
Coordinators: Francisco Mijangos, MD/ Patricia Baz, MD11:40 – 13:00
11:40 – 11:50 Interactive Clinical case discussion Fransisco Zazueta, MD
11:50 – 12:10 Quantifying the risk: Who patients requires less/more intensive treatment? Myrna Candelaria, MD
12:10 – 12:25 Mutations & cytogenetic alterations implicated in evolution to acute leukemia Farhad Ravandi, MD
12:25 – 12:40 Advances in treatment in MDS Guillermo García-Manero, MD
AMSDAC PRESENTATION (10')
12:50 – 13:00 Questions & Answers (Round Table) All of the Participants
September 3rd/SaturdayBest of ASCO
Hemato/Oncology AbstractsRoom: Coral Garden
13:00 – 15:00
13:00 – 13:15 Hematologic Malignancies Speaker: Flavio A. Grimaldo, MD
Abstract ID: 7000Jeffrey E. Lancet, MD., Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML.Abstract ID: 7001Andreas Hochhaus, MD., Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CMLCP) treated with frontline nilotinib: Results from the ENESTFreedom study.
13:15 – 13:30 Hematologic Malignancies Leukemia, Myelodysplastic Syndromes and, Allotransplant Speaker: Roberta de Michelis, MD
Abstract ID: 7008Jorge E. Cortes, MD., Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.Abstract ID: 7009Daniel Aaron Pollyea, MD., Results of a phase 1b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients ≥ 65 years ineligible for standard induction therapy.
Coordinator: Carlos Cadena, MD
13:30 – 13:45 Hematologic Malignancies Lymphoma and Chronic Lymphocytic Lymphoma Speaker: Ana Ramírez Ibarguen, MD
Abstract ID: 7501Adrienne Alise Phillips, MD., A prospective, multicenter, randomized study of anti-CCR4 monoclonal antibody mogamulizumab (moga) vs investigator's choice (IC) in the treatment of patients (pts) with relapsed/refractory (R/R) adult T-cell leukemia-lymphoma (ATL).
September 3rd/Saturday
Abstract ID: 7503Mathias J. Rummel, MD., Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial).
13:45 – 14:10 Hematologic Malignancies Lymphoma and Chronic Lymphocytic Lymphoma Speaker: Luis Villela, MD
Abstract ID: 7504Pieternella J. Lugtenburg, MD., Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or no maintenance in patients with diffuse large B- cell lymphoma: Results from a HOVON-Nordic Lymphoma Group study.
Abstract ID: 7506Thomas E. Witzig, MD., PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL).
Abstract ID: 7508Steven i. Park, MD., A phase 2 trial of ABVD followed by brentuximab vedotin consolidation in limited stage non-bulky Hodgkin lymphoma.
Coordinator: Silvia Rivas Vera, MD
14:10 – 14:30 Hematologic Malignancies Plasma Cell Dyscrasia Speaker: Rafael Fonseca, M.D.
Abstract ID: LBA4Antonio Palumbo, MD., Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study.
Abstract ID: 8000Michael Cavo, MD., Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial).
September 3rd/Saturday
Abstract ID: 8001Michael Attal, MD., Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS).
14:30 – 14:45 Hematologic Malignancies Plasma Cell Dyscrasia Speaker: Yanet Ventura, M.D.
Abstract ID: 8003Sham Mailankody, MD., Genetic plasma cell signatures in high-risk smoldering myeloma versus multiple myeloma patients.
Abstract ID: 8009Ravi Vij, MD., A phase Ib dose escalation trial of isatuximab (SAR650984, anti-CD38 mAb) plus lenalidomide and dexamethasone (Len/Dex) in relapsed/refractory multiple myeloma (RRMM): Interim results from two new dose cohorts.
Coordinator: Sergio Sánchez, M.D.
14:45 – 15:00 Pannel Discussion Q/A
DEBATE: EDUARDO CERVERA CEBALLOS, M.D.All of International guest Professors
September 4th/Sunday
MULTIPLE MYELOMA ADVISORY BOARD(By an unrestricted scientific grant by CELGENE)
By invitation only
Information & Online Register
www.incan-mexico.org
+52 (55) 5663-2803 / +52 (55) 5663-0402www.intermeeting.com.mx
CostSpecialists
$350.00 USDResidents
$150.00 USDTransfer or bank deposit
Banco SantanderInstituto Nacional de Cancerología
Cta. N° 65502136852CLABE: 014180655021368529